anti- CCR10 antibody

Background

C-C Chemokine Receptor Type 10 (CCR10) is a G-protein-coupled receptor (GPCR) that binds to two chemokine ligands: CCL27 and CCL28. CCR10 plays a pivotal role in skin and mucosal immunity, primarily regulating the migration of T lymphocytes and other immune cells to tissues such as the epidermis and mucosal surfaces. Its ligand CCL27 is highly expressed in keratinocytes, promoting homing of CCR10-expressing T cells to the skin, which is essential for maintaining cutaneous immune surveillance. This mechanism is also involved in inflammatory skin diseases such as psoriasis and atopic dermatitis, where excessive T-cell recruitment to the skin contributes to chronic inflammation and tissue damage. On the other hand, CCL28 expression is upregulated in mucosal tissues like the respiratory and gastrointestinal tracts, guiding immune cells expressing CCR10 to these sites to protect against pathogens. CCR10 is highly relevant in the context of allergic diseases, autoimmune skin conditions, and cancer, where dysregulated expression enables tumor cells to evade immune responses or promote metastasis. In cancers, such as melanoma and breast cancer, CCR10 has been associated with tumor progression due to its role in immune cell trafficking and metastasis to skin and mucosal tissues. CCR10 is also a potential target for immunotherapy, as inhibiting its signaling pathway could reduce chronic inflammation or prevent tumor immune escape. Thus, CCR10 is a critical chemokine receptor bridging immunity, inflammation, and oncology, making it a promising candidate for therapeutic interventions.